Canaccord Genuity Reiterates a ‘Buy’ Rating on Exactech (EXAC); Silverbolt Acquisition Adds Fifferentiated MIS Product

By · August 30, 2010 · No comments
Spine · Tagged: , ,

Canaccord Genuity reiterates a 'Buy' rating on Exactech, Inc. (Nasdaq: EXAC), lowers PT from $26 to $23.50.

Canaccord analyst says, "We reiterate our rating as the acquisition further strengthens the company's spine portfolio with the addition of a minimally invasive system. Furthermore, given the dynamics of the spine market right now, the new products provide Exactech’s reps additional breadth to bid on the RFPs (request for proposals) that hospitals are putting out, giving the company opportunities to take market share."

To see all the upgrades/downgrades on shares of EXAC, visit our Analyst Ratings page.

Shares are down $0.31 (-2.05%) today to $14.83 and are getting closer to the 52-wk low ($13.54 - 22.34).

Posted By

Josh Sandberg has been recruiting specifically in the musculoskeletal industry for over 8 years. Throughout this time, he has been able to have a positive impact on his client’s businesses. With an educational background in Business Management, Josh is adept to discern which people will be the best fit for the company he is searching for by understanding how candidates will incorporate with the company’s culture and operational nuances. His experience as an executive in a start-up business has granted him the ability to understand what is takes to thrive in a hands–on environment, where desire and dedication are paramount for success.
←
→

© 2012 OrthoSpineNews